Antidepressant efficacy comparison
Pro Research Analysisby 
Searched over 200M research papers
Antidepressant Efficacy Comparison in Adults with Major Depression
Efficacy of Antidepressants Compared to Placebo
Large-scale meta-analyses consistently show that all commonly prescribed antidepressants are more effective than placebo for adults with major depressive disorder. Odds ratios (ORs) for efficacy range from about 1.37 for reboxetine (least effective) to 2.13 for amitriptyline (most effective), with all drugs outperforming placebo to varying degrees 26. This finding is robust across different studies and methodologies.
Head-to-Head Efficacy: Differences Among Antidepressants
When directly comparing antidepressants, some drugs show modestly higher efficacy. Escitalopram, mirtazapine, venlafaxine, and sertraline are often found to be more effective than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine 16. Reboxetine, fluvoxamine, trazodone, and fluoxetine tend to be among the least effective options in these analyses 16. However, the differences in efficacy between most antidepressants are relatively small, and the clinical significance of these differences is debated 610.
Acceptability and Tolerability
Acceptability, measured by treatment discontinuation rates, also varies. Escitalopram, sertraline, citalopram, fluoxetine, agomelatine, and vortioxetine are generally better tolerated, leading to fewer dropouts compared to other antidepressants 16. Drugs like amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine have higher dropout rates, often due to side effects . Sertraline is highlighted as having a particularly favorable balance between efficacy, acceptability, and cost .
Dose-Response Relationships
Most antidepressants reach their maximum efficacy at lower or middle doses, rather than at the highest recommended doses. Only a few drugs, such as amitriptyline, clomipramine, and reboxetine, show a clear linear increase in effect with higher doses . For most medications, increasing the dose beyond a certain point does not improve outcomes .
Efficacy in Special Populations
Children and Adolescents
In children and adolescents, the evidence for antidepressant efficacy is weaker. Only fluoxetine shows a statistically significant benefit over placebo, and the overall quality of evidence is low. Other antidepressants do not demonstrate clear advantages, and some (imipramine, venlafaxine, duloxetine) are associated with higher rates of discontinuation due to side effects .
Post-Stroke Depression
For post-stroke depression, escitalopram provides quicker relief, but mirtazapine may be the most effective after 8 weeks of treatment. Amitriptyline and doxepin are generally less effective regardless of treatment duration 89. Paroxetine may offer the best balance of efficacy and acceptability in this group .
Antidepressants vs. Cognitive Behavioral Therapy (CBT)
Antidepressant medications are slightly more effective than cognitive behavioral therapy (CBT) for some specific symptoms of depression, such as depressed mood, guilt, suicidal thoughts, and anxiety. However, for most symptoms, there is no significant difference between medication and CBT .
Methodological Considerations and Limitations
Some researchers caution that network meta-analyses, which are commonly used to compare antidepressant efficacy, may overstate differences between drugs due to methodological limitations. Simulations suggest that these analyses can produce false positives, making it appear that some drugs are superior when true differences may be minimal or nonexistent . Therefore, while some antidepressants may appear more effective in meta-analyses, these differences should be interpreted with caution.
Conclusion
All antidepressants are more effective than placebo for adults with major depression, but differences in efficacy between individual drugs are generally small. Escitalopram, sertraline, mirtazapine, and venlafaxine are among the most effective and acceptable options for adults, while fluoxetine is the best-supported choice for children and adolescents. For most patients, maximum benefit is achieved at lower or middle doses. Methodological issues in comparative studies mean that claims of superiority for specific drugs should be viewed carefully. Ultimately, the choice of antidepressant should consider efficacy, tolerability, patient preference, and cost.
Sources and full results
Most relevant research papers on this topic